Single-cell RNA-seq Reveals Fibroblast Heterogeneity and Increased Mesenchymal Fibroblasts in Human Fibrotic Skin Diseases
Overview
Authors
Affiliations
Fibrotic skin disease represents a major global healthcare burden, characterized by fibroblast hyperproliferation and excessive accumulation of extracellular matrix. Fibroblasts are found to be heterogeneous in multiple fibrotic diseases, but fibroblast heterogeneity in fibrotic skin diseases is not well characterized. In this study, we explore fibroblast heterogeneity in keloid, a paradigm of fibrotic skin diseases, by using single-cell RNA-seq. Our results indicate that keloid fibroblasts can be divided into 4 subpopulations: secretory-papillary, secretory-reticular, mesenchymal and pro-inflammatory. Interestingly, the percentage of mesenchymal fibroblast subpopulation is significantly increased in keloid compared to normal scar. Functional studies indicate that mesenchymal fibroblasts are crucial for collagen overexpression in keloid. Increased mesenchymal fibroblast subpopulation is also found in another fibrotic skin disease, scleroderma, suggesting this is a broad mechanism for skin fibrosis. These findings will help us better understand skin fibrotic pathogenesis, and provide potential targets for fibrotic disease therapies.
Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway.
Wang Y, Zhang T, Song H, Yang C Sci Rep. 2025; 15(1):8444.
PMID: 40069312 PMC: 11897129. DOI: 10.1038/s41598-025-92687-1.
The HOX code of human adult fibroblasts reflects their ectomesenchymal or mesodermal origin.
Pfeiferova L, Spanko M, Sachova J, Hradilova M, Pienta K, Valach J Histochem Cell Biol. 2025; 163(1):38.
PMID: 40063181 PMC: 11893657. DOI: 10.1007/s00418-025-02362-9.
Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity.
Vecin N, Balukoff N, Yaghi M, Gonzalez T, Sawaya A, Strbo N JID Innov. 2025; 5(3):100350.
PMID: 40034103 PMC: 11872476. DOI: 10.1016/j.xjidi.2025.100350.
Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis.
Lin H, Wang X, Chung M, Cai S, Pan Y J Transl Med. 2025; 23(1):240.
PMID: 40016790 PMC: 11869441. DOI: 10.1186/s12967-024-06060-3.
Yu H, Zhong T, Xu Y, Zhang Z, Ma J, Yuan J Exp Hematol Oncol. 2025; 14(1):18.
PMID: 40001256 PMC: 11852861. DOI: 10.1186/s40164-025-00596-w.